CAXTON CORP
Long book
$4.0M
Q1 2026
Positions
7
Top-10 weight
100%
concentration
Last quarter
-9.4%
SPY +14.8%
Turnover
50%
of book per quarter
Strategy in plain words
auto-generated from filingsCAXTON CORP is a wealth-management firm allocating client money, specialised in financials (90% of the long book), running a $4.0M US long book across 7 positions.
The portfolio is extremely concentrated — the top 10 positions are almost the whole book. The portfolio is actively managed, with meaningful quarterly turnover. Current anchor positions: SPDR GOLD SHARES, BERKSHIRE HATHAWAY INC-CL B, KYVERNA THERAPEUTICS INC, LEXEO THERAPEUTICS INC, X4 PHARMACEUTICALS INC.
Over the last 9 quarters its long book ran on average 8.9pp per quarter ahead of the S&P 500, beating the index in 7 of 9 quarters. Its holdings are mechanical (indexing / client flows), so position changes carry no stock-picking signal.
Implied long-book return vs S&P 500
methodology: positions priced quarterly, no shorts/options Fund long book S&P 500
Q1 2024
+12.9%
Q2 2024
+19.3%
Q3 2024
+10.9%
Q4 2024
+9.2%
Q1 2025
+42.6%
Q2 2025
+87.4%
Q3 2025
-59.8%
Q4 2025
+7.8%
Q1 2026
-9.4%
Sector allocation
Healthcare 53%
Financials 47%
Long book by quarter
What does CAXTON CORP own?
Q1 2026 13F| Company | Sector | Shares | Value | % of book | Change |
|---|---|---|---|---|---|
| BRK/B BERKSHIRE HATHAWAY INC-CL B | Financials | 727 | $348K | 8.7% | +2.4% |
| KYTX KYVERNA THERAPEUTICS INC | Healthcare | 18.8K | $162K | 4.0% | Held |
| LXEO LEXEO THERAPEUTICS INC | Healthcare | 13.9K | $80K | 2.0% | Held |
| XFOR X4 PHARMACEUTICALS INC | Healthcare | 15.6K | $64K | 1.6% | Held |
| IKT INHIBIKASE THERAPEUTICS INC | Healthcare | 28.5K | $48K | 1.2% | Held |
| ALXO ALX ONCOLOGY HOLDINGS INC | Healthcare | 20.9K | $42K | 1.0% | New |
13F filing history
| Period | Form | Filed | Entries | Reported value | Flags | Source |
|---|---|---|---|---|---|---|
| Q1 2026 | 13F-HR | May 14, 2026 | 7 | $4.0M | confidential canonical | SEC ↗ |
| Q4 2025 | 13F-HR | Feb 13, 2026 | 11 | $4.3M | confidential canonical | SEC ↗ |
| Q3 2025 | 13F-HR | Nov 14, 2025 | 12 | $22.9M | confidential canonical | SEC ↗ |
| Q2 2025 | 13F-HR | Aug 14, 2025 | 11 | $9.9M | confidential canonical | SEC ↗ |
| Q1 2025 | 13F-HR | May 15, 2025 | 12 | $5.1M | confidential canonical | SEC ↗ |
| Q4 2024 | 13F-HR | Feb 14, 2025 | 15 | $16.6M | confidential canonical | SEC ↗ |
| Q3 2024 | 13F-HR | Nov 14, 2024 | 12 | $24.2M | confidential canonical | SEC ↗ |
| Q2 2024 | 13F-HR | Aug 14, 2024 | 12 | $19.7M | confidential canonical | SEC ↗ |
| Q1 2024 | 13F-HR | May 15, 2024 | 11 | $17.6M | confidential canonical | SEC ↗ |